The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales

Vaccine

Volumn 30, Issue 48, 2012, Pages 6766-6776

  Atkins, Katherine E ^a   Shim, Eunha ^b   Carroll, Stuart ^c   Quilici, Sibilia ^d   Galvani, Alison P ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Sanofi Pasteur MSD   (United Kingdom)

^d SANOFI PASTEUR   (France)

Author keywords

Budget impact; Dynamic epidemiological model; Rotavirus gastroenteritis; Threshold analysis

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GASTROENTERITIS; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; UNITED KINGDOM; VACCINATION; VIRUS TRANSMISSION;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; ENGLAND; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED; WALES;

EID: 84868201637     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.025     Document Type: Article

References (58)

1. Patel M.M., Steele D., Gentsch J.R., Wecker J., Glass R.I., Parashar U.D. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30(1):S1-S5.
2. WHO Immunization Monitoring; 2012. URL: http://www.who.int/immunization_monitoring/data/en/.
3. Braeckman T., Van Herck K., Raes M., Vergison A., Sabbe M., Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011, 30(1 Suppl.):S21-S24.
4. Gagneur A., Nowak E., Lemaitre T., Segura J.F., Delaperrière N., Abalea L., et al. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine 2011, 29(21):3753-3759.
5. Giaquinto C., Dominiak-Felden G., Van Damme P., Htar Myint T., Maldonado Y., Vana Spoulou V., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011, 7(7):734-748.
6. Martinon-Torres F., Alejandro M., Collazo L., Lastres J., Diaz S., Pillado M., et al. Prospective evaluation of indirect costs due to acute rotavirus gastroenteritis in Spain: the ROTACOST study. Hum Vaccin 2011, 7(7):757-761.
7. Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29(15):2791-2796.
8. Tate J.E., Mutuc J.D., Panozzo C.A., Payne D.C., Cortese M.M., Cortes J.E., et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011, 30(1):S30-S34.
9. Trimis G., Koutsoumbari I., Kottaridi C., Palaiologou N., Assimakopoulou E., Spathis A., et al. Hospital-based surveillance of rotavirus gastroenteritis in the era of limited vaccine uptake through the private sector. Vaccine 2011, 29(43):7292-7295.
10. Uhlig U., Kostev K., Schuster V., Uhlig H. Rotavirus vaccination in Germany: analysis of nationwide surveillance data 2006 to 2010. PJID 2011, 30(12):e244-e247. 10.1097/INF.0b013e31822d1408.
11. Zeller M., Rahman M., Heylen E., De Coster S., De Vos S., Arijs I., et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28(47):7507-7513.
12. Jit M., Bilcke J., Mangen M.J.J., Salo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27(44):6121-6128.
13. Jit M., Mangen M.J.J., Melliez H., Yazdanpanah Y., Bilcke J., Salo H., et al. An update to " The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe" Vaccine 2010, 28(47):7457-7459.
14. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204(7):980-986.
15. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Weinberg G., Hall C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011, 2006-2009.
16. Atchison C., Lopman B., Edmunds W.J. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010, 28(18):3118-3126.
17. de Blasio B.F., Kasymbekova K., Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 2010, 28(50):7923-7932.
18. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325:290-294.
19. Rozenbaum M.H., Mangen M.J.J., Giaquinto C., Wilschut J.C., Hak E., Postma M.J. Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a consensus model. BMC Public Health 2011, 11(1):462.
20. Mangen M.J.J., van Duynhoven Y.T.H.P., Vennema H., van Pelt W., Havelaar A.H., de Melker H.E. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28(14):2624-2635.
21. Shim E., Galvani A.P. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009, 27(30):4025-4030.
22. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27(4):281-297.
23. Atkins K.E., Shim E., Pitzer V.E., Galvani A.P. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30:552-564.
24. Giaquinto C., Van Damme P., Huet F., Gothefors L., Van der Wielen M. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007, 195(Suppl. 1):S36-S44.
25. Jit M., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25:3971-3979.
26. Vesikari T., Itzler R., Karvonen A., Korhonen T., Damme P.V., Behre U., et al. RotaTeq(R), a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2010, 28(2):345-351.
27. ONS. UK population estimates. Office for National Statistics; 2010. URL: PDFS: FM1_27_tcm77-156664 (1988-1998), fm108_tcm77-240737 (1998-2008). http://www.ons.gov.uk/ons/publications/index.html.
28. Mäkelä M., Marttila J., Simell O., Ilonen J. Rotavirus-specific T-cell responses in young prospectively followed-up children. Clin Exp Immunol 2004, 137(1):173-178.
29. Chiba S., Nakata S., Urasawa T., Urasawa S., Yokoyama T., Morita Y., et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. The Lancet 1986, 328(8504):417-421.
30. Vesikari T., Karvonen A., Ferrante S.A., Kuter B.J., Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J 2010, 29(10):957-963.
31. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169(11):1379-1386.
32. Harris J.P., Jit M., Cooper D., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007, 25:3962-3970.
33. Jit M., Pebody R., Chen M., Andrews N., Edmunds J. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccin 2007, 3(1):23-26.
34. CDC. Withdrawal of rotavirus vaccine recommendation. MMWR 48. Tech. Rep.; 1999.
35. CDC. Intussusception among recipients of rotavirus vaccine, United States, 1998-1999. MMWR 48. Tech. Rep.; 1999.
36. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
37. Ruiz-Palacios G., Pérez-Schael I., Velázquez F., Abate H., Breuer T., Clemens S., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
38. Haber P., Patel M., Izurieta H.S., Baggs J., Gargiullo P., Weintraub E., et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008, 121(6):1206-1212.
39. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.
40. Buttery J.P., Lambert S.B., Grimwood K., Nissen M.D., Field E.J., Macartney K.K., et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. Pediatr Infect Dis J 2011, 30(1):S25-S29.
41. Tilson L., Jit M., Schmitz S., Walsh C., Garvey P., McKeown P., et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011, 29(43):7463-7473.
42. WHO Rotavirus vaccine and intussusception: report from an expert consultation. Wkly Epidemiol Rec 2011, 86(30):317-321.
43. WHO Global Advisory Committee on Vaccine Safety, December 2011. Wkly Epidemiol Rec 2012, 87(6):53-59.
44. NICE. Guide to the methods of technology appraisal. Tech. Rep. June; NICE; 2008.
45. NHS. National schedule of reference costs year: '2010-11' - NHS trusts and PCTs combined non-elective inpatient (long and short stay). HRG data. Appendix NSRC4. Tech. Rep.; 2011.
46. Santos A.C., Roberts J.A., Cook A.J.C., Simons R., Sheehan R., Lane C., et al. Salmonella Typhimurium and Salmonella Enteritidis in England: costs to patients, their families, and primary and community health services of the NHS. Epidemiol Infect 2011, 139(5):742-753. http://www.ncbi.nlm.nih.gov/pubmed/20598211, 10.1017/S0950268810001615.
47. Curtis L. Unit costs of health and social care. Personal Social Services Research Unit. Tech. Rep.; 2011.
48. Carroll S., Adlard N., Gibbons B., Martin S., Pym N. Evaluation of consultation time for paediatric vaccines. Health protection agency annual conference. Poster presentation. Health protection agency annual conference 2010.
49. Senecal M., Brisson M., Lebed M.H. Burden of rotavirus associated gastroenteritis in Canadian families: a prospective community based study. Seventh Canadian immunization conference 2006.
50. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22(3):259-267.
51. Department of Health JCVI; 2011. http://www.dh.gov.uk/ab/JCVI/DH_128454.
52. Ibuka Y., Paltiel A.D., Galvani A.P. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. Med Decis Making 2012, 32(3):442-446. http://www.ncbi.nlm.nih.gov/pubmed/22472916, 10.1177/0272989X12441397.
53. Van Effelterre T., Soriano-Gabarró M., Debrus S., Claire Newbern E., Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010, 138(6):884-897.
54. Linhares A.C., Gabbay Y.B., Freitas R.B., da Rosa E.S.T., Mascarenhas J.D.P., Loureiro E.C.B. Longitudinal study of rotavirus infections among children from Belém, Brazil. Epidemiol Infect 1989, 102(1):129-145.
55. Widdowson M.A., Meltzer M.I., Zhang X., Bresee J.S., Parashar U.D., Glass R.I. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119(4):684-697.
56. Heymann D. Gastroenteritis, acute viral. Control of communicable diseases manualPlease supply the name of the city of publication of Ref. [56].-> 2004, 224-227. American Public Health Association. 18th ed. D. Heymann (Ed.).
57. NHS. National schedule of reference costs year: '2010-11' - NHS trusts and PCTs combined accident and emergency services: leading to admitted. Appendix NSRC4. Tech. Rep.; 2011.
58. Pitzer V., Atkins K.E., Birgitte Freiesleben de B., Van Effelterre T., Atchison C.J., Harris J.P., et al. Direct and Indirect Effects of Rotavirus Vaccination: Comparing Predictions from Transmission Dynamic Models. PLoS ONE 2012, 7(8):e423.